Anna Wolska1, Zhi-Hong Yang, Alan T Remaley. 1. Lipoprotein Metabolism Laboratory, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Abstract
PURPOSE OF REVIEW: Hypertriglyceridemia (HTG), a form of dyslipidemia characterized by elevated plasma of triglycerides (TG), is associated with an increased risk for acute pancreatitis. Moreover, HTG has recently been shown to be linked to the development of atherosclerotic cardiovascular disease (ASCVD); therefore, there is a great interest in better understanding the pathophysiology of HTG and improving its clinical management. In this review, we briefly describe TG metabolism, recent guidelines for the clinical management of HTG and provide an overview of the current and potential new therapies for HTG. RECENT FINDINGS: Screening patients for HTG is valuable for not only identifying patients with extreme TG elevations, who are at risk for pancreatitis, but also for managing ASCVD risk in patients with more moderate forms of HTG. Therefore, the most recent USA guidelines for cardiovascular diseases recommend using TG as a risk enhancer test, leading to a more aggressive treatment of patients with intermediate risk. Currently, there are several available approaches for reducing plasma TG, which include lifestyle changes, fibrates and omega-3 fatty acid treatment. The addition of eicosapentaenoic acid (EPA) on top of statins has recently been shown to significantly reduce ASCVD events. Nevertheless, there is an unmet need for more effective treatment options. Several new therapies based on newly identified targets in TG metabolism, such as apolipoprotein C-III and angiopoietin-like 3 protein, are currently under development. SUMMARY: The clinical management of HTG is important in the prevention and treatment of acute pancreatitis and also impacts on how ASCVD risk is managed. More work needs to be done to establish the mechanism for the ability of how EPA lowers ASCVD and how to best integrate it with other lipid-lowering therapies. The efficacy and safety of the novel therapies for HTG should be established soon in the ongoing late-stage clinical trials.
PURPOSE OF REVIEW: Hypertriglyceridemia (HTG), a form of dyslipidemia characterized by elevated plasma of triglycerides (TG), is associated with an increased risk for acute pancreatitis. Moreover, HTG has recently been shown to be linked to the development of atherosclerotic cardiovascular disease (ASCVD); therefore, there is a great interest in better understanding the pathophysiology of HTG and improving its clinical management. In this review, we briefly describe TG metabolism, recent guidelines for the clinical management of HTG and provide an overview of the current and potential new therapies for HTG. RECENT FINDINGS: Screening patients for HTG is valuable for not only identifying patients with extreme TG elevations, who are at risk for pancreatitis, but also for managing ASCVD risk in patients with more moderate forms of HTG. Therefore, the most recent USA guidelines for cardiovascular diseases recommend using TG as a risk enhancer test, leading to a more aggressive treatment of patients with intermediate risk. Currently, there are several available approaches for reducing plasma TG, which include lifestyle changes, fibrates and omega-3 fatty acid treatment. The addition of eicosapentaenoic acid (EPA) on top of statins has recently been shown to significantly reduce ASCVD events. Nevertheless, there is an unmet need for more effective treatment options. Several new therapies based on newly identified targets in TG metabolism, such as apolipoprotein C-III and angiopoietin-like 3 protein, are currently under development. SUMMARY: The clinical management of HTG is important in the prevention and treatment of acute pancreatitis and also impacts on how ASCVD risk is managed. More work needs to be done to establish the mechanism for the ability of how EPA lowers ASCVD and how to best integrate it with other lipid-lowering therapies. The efficacy and safety of the novel therapies for HTG should be established soon in the ongoing late-stage clinical trials.
Authors: Anette Varbo; Marianne Benn; Anne Tybjærg-Hansen; Anders B Jørgensen; Ruth Frikke-Schmidt; Børge G Nordestgaard Journal: J Am Coll Cardiol Date: 2012-12-19 Impact factor: 24.094
Authors: Yan Wang; Viktoria Gusarova; Serena Banfi; Jesper Gromada; Jonathan C Cohen; Helen H Hobbs Journal: J Lipid Res Date: 2015-05-07 Impact factor: 5.922
Authors: Toshihiro Sakurai; Akiko Sakurai; Boris L Vaisman; Marcelo J Amar; Chengyu Liu; Scott M Gordon; Steven K Drake; Milton Pryor; Maureen L Sampson; Ling Yang; Lita A Freeman; Alan T Remaley Journal: J Pharmacol Exp Ther Date: 2015-11-16 Impact factor: 4.030
Authors: Fredrik Rosqvist; Catriona A McNeil; Camilla Pramfalk; Sion A Parry; Wee Suan Low; Thomas Cornfield; Barbara A Fielding; Leanne Hodson Journal: Am J Clin Nutr Date: 2019-02-01 Impact factor: 7.045
Authors: Martin J Landray; Richard Haynes; Jemma C Hopewell; Sarah Parish; Theingi Aung; Joseph Tomson; Karl Wallendszus; Martin Craig; Lixin Jiang; Rory Collins; Jane Armitage Journal: N Engl J Med Date: 2014-07-17 Impact factor: 91.245
Authors: Shiwali Goyal; Yosuke Tanigawa; Weihua Zhang; Jin-Fang Chai; Marcio Almeida; Xueling Sim; Megan Lerner; Juliane Chainakul; Jonathan Garcia Ramiu; Chanel Seraphin; Blair Apple; April Vaughan; James Muniu; Juan Peralta; Donna M Lehman; Sarju Ralhan; Gurpreet S Wander; Jai Rup Singh; Narinder K Mehra; Evgeny Sidorov; Marvin D Peyton; Piers R Blackett; Joanne E Curran; E Shyong Tai; Rob van Dam; Ching-Yu Cheng; Ravindranath Duggirala; John Blangero; John C Chambers; Charumathi Sabanayagam; Jaspal S Kooner; Manuel A Rivas; Christopher E Aston; Dharambir K Sanghera Journal: Lipids Health Dis Date: 2021-09-21 Impact factor: 3.876
Authors: Amanda J Berberich; Alexandra M Ouédraogo; Salimah Z Shariff; Robert A Hegele; Kristin K Clemens Journal: Lipids Health Dis Date: 2021-09-03 Impact factor: 3.876